← All trials
NCT06582524
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Sep 3, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 3
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Immedica Pharma ABLead sponsor
- Immedica Pharma ABOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.